Peijia Medical’s TaurusNXT TAVR System Registration Application Accepted by NMPA

Peijia Medical Limited announced that the National Medical Products Administration (NMPA) of China has accepted the registration application for its TaurusNXT® Non-glutaraldehyde Crosslinked Dry-tissue Transcatheter Aortic Valve Replacement (TAVR) system. The system has been admitted to the Special Review and Approval Procedure for Innovative Medical Devices, which will prioritize its subsequent appraisal and approval processes. No grant or funding from multiple organizations was mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Peijia Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251207-11947167), on December 07, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.